ICU Medical

ICU Medical Announces First Quarter 2024 Results

Retrieved on: 
星期二, 五月 7, 2024
Use, ICU, Sale, Bank statement, ICU Medical, ICUI, GAAP, SAN

SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024.

Key Points: 
  • SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024.
  • First quarter 2024 revenue was $566.7 million, compared to $568.6 million in the same period in the prior year.
  • Adjusted diluted earnings per share for the first quarter of 2024 was $0.96 as compared to $1.74 for the first quarter of 2023.
  • Adjusted EBITDA was $78.8 million for the first quarter of 2024 as compared to $102.0 million for the first quarter of 2023.

Diality Welcomes Ravi Parthasarathy as Chief Technology Officer

Retrieved on: 
星期二, 五月 7, 2024
Medical Devices, Health, Kidney disease, Motorola, Moda, Research, Baxter International, ICU Medical, General Motors, Patient, CSO, Inc., Quality of life, Management

Diality Inc. , a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.

Key Points: 
  • Diality Inc. , a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.
  • Parthasarathy comes to Diality with decades of product development team leadership experience, most recently with ICU Medical, where he served as Vice President, Device Engineering.
  • Prior to ICU Medical, he served in leadership and product development roles for Baxter Healthcare, Motorola, Siemens Medical Systems, and General Motors.
  • “We are delighted to welcome someone of Ravi’s expertise and passion to Diality,” said Osman Khawar, M.D., CEO of Diality.

ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call

Retrieved on: 
星期二, 四月 23, 2024
Sale, ICU Medical, ICUI, SAN

SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call.

Key Points: 
  • SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call.
  • The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m.
  • ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m.
  • ET (1:30 p.m. PT) on Tuesday, May 7th, 2024.

ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor Forum

Retrieved on: 
星期三, 三月 13, 2024
Webcast, SAN, ICUI, ICU Medical, ICU, Sale, Medtech

SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024.

Key Points: 
  • SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024.
  • ICU Medical’s presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m.
  • Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024.
  • The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com , clicking on the Investors tab and clicking on the Event Calendar tab.

ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference

Retrieved on: 
星期五, 三月 1, 2024
SAN, ICU, ICU Medical, Sale, Conference, ICUI, Webcast

SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024.

Key Points: 
  • SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024.
  • ICU Medical’s presentation will be on Monday, March 4, 2024 at 4:30 a.m. PT (7:30 a.m.
  • Company management will also be participating in one-on-one meetings on Monday, March 4, 2024.
  • The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com , clicking on the Investors tab and clicking on the Event Calendar tab.

ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance

Retrieved on: 
星期二, 二月 27, 2024
ICU Medical, SAN, ICUI, Use, GAAP, Sale, ICU, Bank statement

Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year.

Key Points: 
  • Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year.
  • GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the same period in the prior year.
  • Adjusted diluted earnings per share for the fourth quarter of 2023 was $1.57 as compared to $1.60 for the fourth quarter of 2022.
  • Also, adjusted EBITDA was $86.3 million for the fourth quarter of 2023 as compared to $96.4 million for the fourth quarter of 2022.

Global IV Catheters Market Insights Report 2023-2029: Peripheral Inserted Central Catheters (PICCs) Leading the Charge - ResearchAndMarkets.com

Retrieved on: 
星期五, 二月 23, 2024
Medical Devices, Health, Diabetes, Incidence, Alzheimer's disease, Infection, ICU, USD, European, Ageing, Growth, Cancer, Conditional sentence, Stroke, Hospital, Government, Short, ICU Medical, Prevalence, Safety, Malaria, Nutrient, PICC, Life expectancy, Injury, Patient, Dementia, Tuberculosis, CVC, Developed country, COPD, Medical device

The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%

Key Points: 
  • The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%
    The global IV catheters market report contains exclusive data on 33 vendors.
  • BD, B Braun, Terumo, Teleflex, ICU Medical, and Nipro Medical are some leading players currently dominating the global IV catheters market.
  • The continuous growth in individuals with chronic conditions and the rapidly expanding elderly population are the primary factors fueling the global demand for peripheral IV catheters.
  • The peripheral inserted central catheters (PICCs) product segment accounted for the highest market share of over 45% of the global CIVCs market.

ICU Medical Announces Time of Fourth Quarter 2023 Earnings Conference Call

Retrieved on: 
星期二, 二月 13, 2024
ICU Medical, SAN, ICUI, Sale

SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call.

Key Points: 
  • SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call.
  • The Company will release its fourth quarter 2023 results on Tuesday, February 27th, 2024 at approximately 4:00 p.m.
  • ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m.
  • The call can be accessed at (833) 816-1376, conference ID 10186026.

United States Syringes & Needles Market Insights Report 2023: A $10.87 Billion Market by 2028 with BD, ICU Medical, Nipro Medical, Terumo, and Cardinal Health Emerging as Prominent Players - ResearchAndMarkets.com

Retrieved on: 
星期一, 十二月 11, 2023
Medical Supplies, Health, Nipro, Sale, Syringe, Fungal infection, Conditional sentence, Incidence, ICU Medical, Cardinal Health, Hospital, Needle, Vaccination, Vaccine, Immunization, Cardinal, Diabetes, Anthrax Vaccine Immunization Program

This report offers market size & forecast data for the US syringes & needles market.

Key Points: 
  • This report offers market size & forecast data for the US syringes & needles market.
  • This report provides a comprehensive and current market scenario of the US syringes & needles market, including the US syringes & needles market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present US syringes & needles market and its market dynamics for 2023?2028.
  • BD, ICU Medical, Nipro Corporation, Terumo, and Cardinal Health are the key players in the US syringes and needles market.

Corsair Gaming Reports Third Quarter 2023 Financial Results; 16.5% Revenue Growth Over Prior Year; Updates Full Year Financial Outlook

Retrieved on: 
星期二, 十一月 7, 2023
Technology, Mobile, Wireless, Electronic Games, Audio, Video, Entertainment, Online, Blogging, Apps, Applications, Podcast, Other Technology, Communications, Internet, Hardware, Consumer Electronics, Elgato, Virtuoso, Ecosystem, International, EBITDA, GAAP, Acquisition, FPS, Mouse, Risk, Prompter, ICU Medical, CPU, GPU, K70, LINK, Traction, CRSR, Marketplace, DIY, Corsair Gaming, Bluetooth, Video game, Reinsurance, Corsair, Q3

Net revenue was $363.2 million compared to $311.8 million in the third quarter of 2022, an increase of 16.5%.

Key Points: 
  • Net revenue was $363.2 million compared to $311.8 million in the third quarter of 2022, an increase of 16.5%.
  • Net revenue was $1,042.6 million compared to $976.4 million in the first nine months of 2022, an increase of 6.8%.
  • The robust and successful release of a steady stream of popular new game titles in 2023 is further spurring demand.
  • Corsair will host a conference call to discuss the third quarter 2023 financial results today at 2:00 p.m. Pacific Time.